The Adenosine A2A-Receptor Antagonist Istradefylline Enhances the Motor Response of l-DOPA Without Worsening Dyskinesia in MPTP-Treated Common Marmosets

The adenosine A2A-receptor antagonist istradefylline decreases OFF time in patients with Parkinson’s disease who are already treated with optimal doses of dopaminergic medication but can cause an increase in non-troublesome dyskinesia. Preclinical experiments have shown that A2A antagonists are most...

Full description

Bibliographic Details
Main Authors: Shin-ichi Uchida, Tomomi Tashiro, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda
Format: Article
Language:English
Published: Elsevier 2014-01-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319301707